S. Rafiq

Oncology · 2018–2019

A researcher in the Science corpus: 2 papers; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom S. Rafiq trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Jang-Hwan Cho
  2. R. Morgan
  3. Levi J. Rupp
  4. Michel Sadelain
  5. James J. Collins
  6. Kole T. Roybal
  7. Theodoros Giavridis
  8. Jennifer N. Brudno
  9. Jie Yang
  10. M. Junttila

Papers from S. Rafiq's perspective

Ordered by how strongly the researchers S. Rafiq trusts endorse each paper. Same corpus, a different order for every researcher.

  1. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (Science Translational Medicine)
  2. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia (Science Translational Medicine)
  3. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells (Nature Medicine)
  4. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia (New England Journal of Medicine)
  5. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities (Nature Reviews Clinical Oncology)
  6. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. (Molecular Therapy)
  7. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells (Nature Biotechnology)
  8. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade (Nature Medicine)
  9. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition (Clinical Cancer Research)
  10. Therapeutic T cell engineering (Nature)

Their papers